Historical record - last NADAC effective date: 12/22/2017
Product Information
KALETRA 80 MG-20 MG/ML SOLN is a brand product labeled by AbbVie Inc., priced at $3.1186 per ML under NDC 00074395646. Its NADAC has been published 264 times since Nov 28, 2013.
FDA first approved this application on Sep 15, 2000.
Strength
80; 20 mg/mL; mg/mL
Manufacturer
AbbVie Inc.NDC
00074395646
Classification
Brand
Dosage Form
SOLUTION
Route
ORAL
Effective Date
12/22/2017
Active Ingredients
LOPINAVIR; RITONAVIRApproval Type
New Drug (NDA)
FDA Application
NDA021251FDA Approved
9/15/2000
On Market Since
6/18/2010
Pharmacological Classes
Price Statistics
The NADAC for KALETRA 80 MG-20 MG/ML SOLN has been published 264 times since Nov 28, 2013, and over the history we have for it it has risen 31.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.1186 per ML |
|---|---|
| All-time high | $3.1186 (Dec 12, 2018) |
| All-time low | $2.3689 (Nov 28, 2013) |
| Median price | $2.8073 |
| Average price | $2.7693 |
| Largest weekly change | +6.9% (Jan 6, 2016) |
| Weeks tracked | 264 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+31.6%
Last surveyed Dec 12, 2018 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Lopinavir and Ritonavir market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lopinavir and Ritonavir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cytochrome P450 3A Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KALETRA 80 MG-20 MG/ML SOLN?
The current National Average Drug Acquisition Cost (NADAC) for KALETRA 80 MG-20 MG/ML SOLN, manufactured by AbbVie Inc., is $3.1186 per ML (NDC 00074395646), effective Dec 12, 2018.
How has the price of KALETRA 80 MG-20 MG/ML SOLN changed over time?
Over the history we have for it, the NADAC for KALETRA 80 MG-20 MG/ML SOLN has risen 31.6%. It has been tracked across 264 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for KALETRA 80 MG-20 MG/ML SOLN?
Since Nov 28, 2013, the NADAC for KALETRA 80 MG-20 MG/ML SOLN has ranged from a low of $2.3689 (Nov 28, 2013) to a high of $3.1186 (Dec 12, 2018), with a median of $2.8073 per ML.
Are there cheaper alternatives to KALETRA 80 MG-20 MG/ML SOLN?
No other NADAC-published product currently shares the active ingredient and strength of KALETRA 80 MG-20 MG/ML SOLN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures KALETRA 80 MG-20 MG/ML SOLN?
KALETRA 80 MG-20 MG/ML SOLN (NDC 00074395646) is labeled by AbbVie Inc., and CMS classifies it as a brand product.